Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody ...

On Oct. 15, JNJ’s shares rose 1.6% after it announced its Q3 earnings report. It reported an adjusted profit of $2.42 per ...

Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price target of $181.00. The company’s shares closed ...